Piper Sandler Maintains Neutral on Summit Therapeutics, Lowers Price Target to $16

Benzinga Newsdesk www.benzinga.com Negative 84.0%

Neg 84% Neu 0% Pos 0%

Piper Sandler analyst Kelsey Goodwin maintains Summit Therapeutics (NASDAQ:SMMT) with a Neutral and lowers the price target from $17 to $16.